An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
This month’s list of partnerships, manufacturing facilities, new technologies and other items includes AstraZeneca, Charles River, Veeva, and other firms.
With the launch of its Trialbee Honey technology, the company aims to bring together recruitment information from different sources for sweeter results.
The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.
To fully reap the benefits of tech advances, a company leader advises, a life-sciences firm must embrace change and connection throughout the operation.
RSG Arrive is intended to increase clinical trial participation by offering ground transport, plane rides, hotels, visa procurement, and other services.
A leader from the drug development and manufacturing firm talks about the ways in which advanced digital tools stand to revolutionize the pharma field.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.
The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.
A leader from the pharmaceutical firm talks about some of the most impactful technologies and shares a number of notable advancements made by the company.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
According to two leaders from the healthcare tech firm, improving the way healthcare data is collected, stored, and used can contribute to improved care.
The patient-centric platform firm is gathering representatives from different corners of the industry to work on solutions to drive progress and innovation.
The HIV treatment specialist has sent an application to the agency for tolutegravir, a single-tablet treatment indicated for children living with the virus.
An expert from the IRB and study solutions firm explains how advanced analytics can lead to several benefits, including shortened trial startup timelines.
This month’s news on appointments, expansions, acquisitions and other events includes Nanoform, Elligo Health Research, Curavit, and other organizations.
A representative from the school explains how tools like artificial intelligence and natural language processing can help elevate personalized medicine.
An expert from the CRO explains the evolution of data technologies put to use in clinical studies and offers advice on how to best make them work in trials.
According to the CEO of patient recruitment specialist SubjectWell, keeping up with the specialized needs of virtual studies calls for innovative thinking.
Leaders from ArisGlobal and Eversana explain the benefits of carefully selecting a research partner with a robust set of capabilities to see a project through.
The pharma firm reports molnupiravir was shown to cut risk of hospitalization or death by 50% compared to placebos in a positive interim Phase III analysis.
A study by Charles River finds patients believe the overall quality of healthcare would increase if stakeholders across the life sciences collaborated more.
A leader from Swift Medical describes the company’s skin and wound management technology, and how their tech empowers patient capture of vital information.
The pharmaceutical firm has tapped the decentralized research organization in order to help elevate the inclusivity of its oncology trials at all levels.
Conducted by patient services specialist Greenphire, the survey checks in with contract research organizations and shows how they are approaching obstacles.
A leader from Firma Clinical Research advises that while using RWD can be daunting, putting the data to use can lead to a number of notable advantages.
The protease inhibitor PF-07321332 (co-administered with ritonavir) is designed for patients exposed to (or showing the first signs of) the COVID-19 virus.
As COVID-19 and its variants continue their attack, the agency maintains its position of overseer and giver of advice on various treatments and vaccines.
The cancer-centric pharma firm will collaborate with the Philadelphia-based cancer center to pinpoint new indications and biomarkers for its drug candidate.
A leader from the global clinical research logistics company shares how to weigh the complex aspects of a decentralized trial and craft intelligent strategy.
According to a leader from the health engagement solutions firm, intelligent use of technology tools can add patient-centricity and realism to a study.
Swift Skin and Wound is a digital imaging technology designed to support decentralized clinical trials conducted to evaluate skin and wound treatments.
Two experts from the contract research organization offer advice on planning and executing clinical studies with the unique needs of such patients in mind.
Stakeholders in the Rare Disease Cures Accelerator-Data and Analytics Platform initiative are partnering in hopes of bringing treatments to patients faster.
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
This month’s roundup of new technology, equipment, and industry partnerships includes news from IBM, IQVIA, Mediata, Labcorp, and other notable companies.
A physician assistant from Hawthorne Effect shares how she and other trained health professionals contribute their knowledge and talents to in-home studies.
A survey commissioned by Bristol Myers Squibb reveals healthcare providers are confident that immunotherapy can positively impact earlier-stage cancers.
The advocacy organization's PIE4CNS initiative is aimed at targeting and reducing gaps in diagnosis, research, and trials for rare neurological conditions.
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The two companies are collaborating on development of Myfembree, a combination therapy to treat the painful condition affecting millions of women worldwide.
The US agency continues to oversee vaccine and drug development, and to share information and advice for life-sciences professionals and civilians alike.
The digital therapeutics firm's Neuroglee Connect remote care platform and virtual clinic is for patients with mild cognitive impairment, including Alzheimer’s.
A leader from the trial tech firm discusses the pandemic’s impact on studies, and how decentralized technology will be vital in helping industry recovery.
Two leaders from the decentralized trial solutions provider discuss the complex pieces of a global clinical study and how to work to fit them all together.
